113.26
0.42%
-0.57
前日終値:
$113.83
開ける:
$113.51
24時間の取引高:
2.45M
Relative Volume:
0.55
時価総額:
$196.90B
収益:
$41.22B
当期純損益:
$5.77B
株価収益率:
34.43
EPS:
3.29
ネットキャッシュフロー:
$6.49B
1週間 パフォーマンス:
+0.49%
1か月 パフォーマンス:
-1.95%
6か月 パフォーマンス:
+8.97%
1年 パフォーマンス:
+2.30%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
113.29 | 196.90B | 41.22B | 5.77B | 6.49B | 3.29 |
SYK
Stryker Corp
|
360.60 | 137.06B | 21.97B | 3.59B | 3.21B | 9.33 |
BSX
Boston Scientific Corp
|
91.28 | 133.94B | 15.91B | 1.79B | 1.89B | 1.21 |
MDT
Medtronic Plc
|
79.92 | 103.77B | 33.00B | 4.29B | 5.50B | 3.27 |
EW
Edwards Lifesciences Corp
|
73.35 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-08 | 開始されました | Oppenheimer | Outperform |
2024-09-19 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-20 | 繰り返されました | Barclays | Overweight |
2023-04-20 | 繰り返されました | Bernstein | Outperform |
2023-04-20 | 繰り返されました | JP Morgan | Overweight |
2023-04-20 | 繰り返されました | Raymond James | Outperform |
2023-04-20 | 繰り返されました | UBS | Buy |
2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
2023-03-29 | 開始されました | UBS | Buy |
2022-10-26 | 開始されました | Mizuho | Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-06 | 開始されました | Wolfe Research | Underperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | UBS | Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
2021-10-14 | 開始されました | Redburn | Neutral |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
2020-09-11 | 開始されました | Wolfe Research | Outperform |
2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
2018-11-30 | アップグレード | Goldman | Neutral → Buy |
2018-10-16 | 開始されました | Barclays | Overweight |
2018-06-27 | 開始されました | Bernstein | Outperform |
2018-01-30 | 繰り返されました | Citigroup | Neutral |
2018-01-25 | 繰り返されました | Stifel | Buy |
2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Pensionfund Sabic Purchases Shares of 25,000 Abbott Laboratories (NYSE:ABT) - MarketBeat
Is Abbott Laboratories (NYSE:ABT) the Best January Dividend Stock to Buy? - Insider Monkey
Abbott and 6 other diagnostic stocks to benefit from HMPV virus concerns in India - Trade Brains
Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt - Yahoo Finance
Abbott Laboratories stock rises Friday, still underperforms market - MarketWatch
Abbott Laboratories (NYSE:ABT) Position Raised by Everence Capital Management Inc. - MarketBeat
Big Pharma Partnering Terms and Agreements Analysis Report 2024 with Directory of Over 2,000 Deals Signed Since 2020 - GlobeNewswire Inc.
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Earnings Preview: What to Expect From Abbott's Report - MSN
Food Intolerance Products Market Size to Reach $22,654.4 Million by 2031: Nestle, General Mills, Abbott - EIN News
GAMMA Investing LLC Grows Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Hemoglobin A1c (HbA1c) Testing Market Projected to Reach $1.83 Billion by 2024, Growth Fueled by Rising Prevalence of Diabetes - GlobeNewswire Inc.
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
PediaSure, Similac Class Action Lawsuit Claims Abbott Lied About Infant Formula Nutritional Value - AboutLawsuits.com
Abbott Laboratories (NYSE:ABT) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
Abbott, Dexcom agree to 10-year truce over diabetes sensor patent litigation - Fierce Biotech
Abbott, Dexcom settle glucose monitor patent lawsuits - MedTech Dive
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Jim Cramer’s Take on Abbott Laboratories (ABT): Bold Predictions for the Future - Insider Monkey
Abbott Laboratories (NYSE:ABT) Shares Unloaded Sen. Markwayne Mullin - MarketBeat
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories (NYSE:ABT) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Abbott Laboratories (NYSE:ABT) Sees Significant Drop in Short Interest - MarketBeat
Deep Venous Disease Treatment Market Top PlayersAbbott - openPR
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Reckitt shares dive as Abbott forced to pay $495m baby formula damages - MSN
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
How Is The Market Feeling About Abbott Laboratories? - Benzinga
Abbott Laboratories (NYSE:ABT) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Simply Wall St
Why Is Abbott Laboratories (ABT) Among Diamond Hill Capital’s Top Stock Picks? - Insider Monkey
Is Abbott Stock Worth Buying at a Discounted P/S Valuation? - MSN
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
Abbott and DexCom settle glucose monitor patent disputes - HealthLeaders Media
Abbott Laboratories (NYSE:ABT) is largely controlled by institutional shareholders who own 77% of the company - Yahoo Finance
February 2025 Options Now Available For Abbott Laboratories (ABT) - Nasdaq
Abbott Labs Settles Pregnancy Bias Suit With Laid-Off Employee - Bloomberg Law
Coronary Balloon Products Market Key Players AnalysisAbbott - openPR
The Art of Valuation: Discovering Abbott Laboratories's Intrinsi - GuruFocus.com
The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value - Yahoo Finance
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Abbott Laboratories stock rises Tuesday, still underperforms market - MarketWatch
Abbott, DexCom Settle Patent Disputes on Glucose Monitor Tech - Bloomberg Law
DexCom, Abbott Agree to Settlement in Patent Litigation - The Wall Street Journal
Abbott Laboratories stock rises Monday, still underperforms market - MarketWatch
Abbott Laboratories' (NYSE:ABT) investors will be pleased with their respectable 43% return over the last five years - Yahoo Finance
M&T Bank Corp Sells 65,012 Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline - Seeking Alpha
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):